Disappointing End For MolMed’s Zalmoxis Cell Therapy In EU
Real World Data Played A Key Role In The Drug’s Initial Approval
Executive Summary
MolMed decided to the withdraw the drug's conditional marketing authorization after Phase III clinical trial results showed that the drug offered no benefit on disease-free survival.
You may also be interested in...
EU Gene Therapy Submissions, Approvals Expected To Pick Up In 2021
Coming year could feature first-time approvals in the EU for at least five gene therapies.
EMA Discusses Pivotal Role Of RWE For Six Drugs
The European Medicines Agency explains how it used real-word evidence during recent deliberations for six products.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.